EGFR and colorectal carcinoma: In a recent Chinese study [10], 32 CRC were investigated by whole exome sequencing (WES), revealing a mutation rate of 59.38% in APC and of 50% in TP53. Because KRAS mutations are predictors of resistance to anti-EGFR antibodies [11], their prevalence in CRC has been extensively investigated, and it is estimated to be approximately 35–45%, similarly to our results.